(redirected from Dexamethasone suppression test)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.


The “storm-time” component of variation of the terrestrial magnetic field, that is, the component which correlates with the interval of time since the onset of a magnetic storm; used as an index of intensity of the ring current.


Daylight-Saving Time.


(1) (DeSTination) Contrast with SRC, which is an abbreviation of "source."

(2) (Digital Signal Trust Company, Salt Lake City, UT) An organization that set up and managed PKI systems for companies and industry groups. Using third-party software, DST served as a certification authority (CA), managed the repository and provided a secure location for the private keys. Founded in 1996, Utah-based DST was the first licensed CA in the U.S. and the first PKI service organization, and Utah was the first state to pass digital signature legislation. In 2002, DST was acquired by Identrus LLC (www.identrus.com), a global leader in digital trust services and secure e-commerce. See PKI.

(3) (Data Storage Technology) An earlier high-capacity magnetic tape technology from Ampex that was based on the digital composite D2 format for the broadcasting industry. It used the same 19mm, helical scan transport, but provided higher capacities with Ampex's proprietary Data D-2 (DD2) format. DST cartridges ranged from 50 to 330GB. Ampex's Data Instrumentation Systems (DIS) tape technology was a counterpart line that provided optional modes and interfaces for data acquisition devices. See magnetic tape.

DST Tape Storage
DST was not exactly for home computer use. The 4mm DAT cassette is shown for size comparison.
References in periodicals archive ?
CS: Cushing's syndrome; UFC: urinary free cortisol; LNSC: late-night salivary cortisol; DST: overnight dexamethasone suppression test; LDST: low-dose dexamethasone suppression test.
In patients with renal failure, the recommended screening test is the 1-mg dexamethasone suppression test. In patients on antiepileptic drugs, the 24-hour urine cortisol or bedtime salivary cortisol test is advised, because antiseizure medications enhance the metabolism of dexamethasone.
Testing for autonomous cortisol secretion showed mildly elevated urinary free cortisol (UFC), failure to suppress cortisol on multiple 1-mg overnight dexamethasone suppression tests (DSTs), elevated late-night salivary cortisol, suppressed adrenocorticotropic hormone (ACTH) on multiple tests, and low dehydroepiandrosterone sulfate (DHEA-S) (Table 1).
APW: absolute percent washout; RPW: relative percent washout ; DST: dexamethasone suppression test; CT: computed tomography; CSI: chemical shift magnetic resonance imaging; MRI: magnetic resonance imaging.
* For Cushing's syndrome, administer the overnight dexamethasone suppression test.
The syndrome was defined as a plasma cortisol response greater than or equal to 1.8 mcg/dL to a low-dose dexamethasone suppression test.
Cortisol was 0.09 and 0.07 [micro]mol/L after a repeated 1-mg dexamethasone suppression test. The 24-h urinary excretion of Cortisol was 37.9 nmol, which made the presence of glucocorticoid excess unlikely.
Rates of nonsuppression on the dexamethasone suppression test are substantially higher in this condition than in other kinds of depression, including the melancholic subtype.
The establishment of the differential diagnosis of CS requires assessment of plasma cortisol, ACTH and one or more dynamic tests such as dexamethasone suppression test (DST) (4).
* Patients with a clinically inapparent adrenal mass should have an overnight 1-mg dexamethasone suppression test (to evaluate for subclinical Cushing's syndrome) and plasma or urinary free metanephrines (more sensitive and specific for pheochromocytoma than 24-hour urine catecholamines).
Masses under 3 cm that show no evidence of rapid growth or hormonal change are not likely to become cancerous and should be monitored at yearly intervals with a dexamethasone suppression test. Limited follow-up data suggest that cancer risk tapers off after 3-4 years.